TY -的A2 -科波拉,Vincenzo AU -莫恩,诺拉盟——Mahjoub苏珊盟——Gutzmer拉尔夫盟——Satzger Imke盟——Beutel Gernot盟——Ivanyi菲利普盟——Golpon海科盟——Wattjes,迈克·p . AU - Stangel马丁盟——Skripuletz托马斯PY - 2020 DA - 2020/12/07 TI -神经系统不良事件的诊断和鉴别诊断免疫抑制剂治疗检查站SP - 8865054六世- 2020 AB -治疗与免疫抑制剂检查站(艾多酷)改善了整体存活率及恶性肿瘤发病率甚至癌症治疗在癌症实体与预后不良。自批准第一ICI、ipilimumab治疗先进的黑色素瘤由美国食品和药物管理局(FDA)在2011年,适应症的频谱和艾多酷已经批准,迅速。到目前为止,七种不同艾多酷超过20的迹象。然而,他们的行动的机制会导致几种不良事件(ira)。特别是神经ira是临床相关。尽管他们是罕见的,早期、准确的诊断是具有挑战性的和神经系统疾病和后遗症是致命的。08/2017至03/2020,31名患者接受了ICI治疗在汉诺威医学院和出现神经系统不良事件(N-irAEs)。治疗恶性肿瘤是转移性黑色素瘤,支气管癌、移行细胞癌。所有患者接受全面的神经诊断包括临床检查和核磁共振成像(MRI)。脑脊液(CSF)分析了21个病人和electroneurography执行在22个病人。 Although N-irAEs were suspected in all 31 patients, 11 patients had other conditions leading to neurological symptoms including tumor metastases in seven patients and hemorrhagic or ischemic stroke in four patients. In the following, these patients are referred to as the differential diagnosis (DD) group. Patients with N-irAEs suffered from immune mediated neuropathy (9/20), myositis and/or myasthenic syndrome (6/20), or encephalitis/cerebellitis (5/20). Except for cell count, CSF results did not differ between the N-irAEs and the DD group. Symptoms related to N-irAEs are rather unspecific potentially mimicking other tumor-related symptoms such as metastases. Patients with malignancy are predominantly not treated by neurologists. Because of the complexity of neurological symptoms, detailed neurological investigations in specialized institutions are necessary in patients with new neurological symptoms and need to be critically discussed with treating oncologists. SN - 1687-8450 UR - https://doi.org/10.1155/2020/8865054 DO - 10.1155/2020/8865054 JF - Journal of Oncology PB - Hindawi KW - ER -